Method of treatment of breast cancers over-expressing the SHP2 signature genes

US9181553B2 · kind B2 · utility

Assignee

• Novartis Forschungsstiftung Zweigniederlassung Friedrich Miescher Institute for Biomedical Resear · CH

Inventors

• Mohamed Bentires-Alj · Weil am Rhein, DE
• Nicola Aceto · Reinach, CH
• Michael Stadler · Munich, DE

Key dates

• Filing date: Jun 5, 2012
• Grant date: Nov 10, 2015
• Expiry date: Jun 5, 2032

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12Q2600/158
• WIPO field: Biotechnology
• WIPO sector: Chemistry

Abstract

A method for treating breast cancer in a subject having a breast cancer over-expressing the “SHP2 signature” genes, as compared to normal breast tissue samples, which method comprises the step of administering to said subject a therapeutically effective amount of a modulator of the protein tyrosine phosphatase, non-receptor type 11 (PTPN11) gene or of its gene product (Shp2).